{
  "id": "mhgap#risk_safety_8fdc706d",
  "content": "be involved in medicine choice in a supported\nRemarks decision-making process.\ny The use of lithium should be considered as first-line y Treatment with antipsychotic medicines/mood\nof treatment for bipolar disorder only if clinical and stabilizers should be combined with psychosocial\nlaboratory monitoring are available. Lithium should interventions (see other recommendations in\nonly be prescribed under mental health specialist this module).\nsupervision. If laboratory examinations are not y Acquisition costs can differ substantially and also\navailable or feasible, lithium should be avoided and throughout the world. Recent antipsychotics may\nother mood stabilizers or antipsychotics should have higher costs than older antipsychotics.\nbe considered. Do not prescribe lithium where the\ny Lithium carbonate, sodium valproate (valproic\nlithium supply may be frequently interrupted due to\nacid), carbamazepine and quetiapine (therapeutic\nincreased risk of relapse. Clinicians should conduct\nalternatives: aripiprazole, olanzapine, paliperidone)\nkidney and thyroid function, complete blood\nare available in the WHO EML (13).\ncount, ECG and pregnancy tests before beginning\ntreatment where possible.\n97\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nPSY8. In adults with bipolar disorders in remission, are mood\nstabilizers and antipsychotics effective and safe?",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "risk_safety",
      "referral",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety be involved in medicine choice in a supported\nRemarks decision-making process.\ny The use of lithium should be considered as first-line y Treatment with antipsychotic medicines/mood\nof treatment for bipolar disorder only if clinical and stabilizers should be combined with psychosocial\nlaboratory monitoring are available. Lithium should interventions (see other recommendations in\nonly be prescribed under mental health specialist this module).\nsupervision. If laboratory examinations are not y Acquisition costs can differ substantially and also\navailable or feasible, lithium should be avoided and throughout the world. Recent antipsychotics may\nother mood stabilizers or antipsychotics should have higher costs than older antipsychotics.\nbe considered. Do not prescribe lithium where the\ny Lithium carbonate, sodium valproate (valproic\nlithium supply may be frequently interrupted due to\nacid), carbamazepine and quetiapine (therapeutic\nincreased risk of relapse. Clinicians should conduct\nalternatives: aripiprazole, olanzapine, paliperidone)\nkidney and thyroid function, complete blood\nare available in the WHO EML (13).\ncount, ECG and pregnancy tests before beginning\ntreatment where possible.\n97\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nPSY8. In adults with bipolar disorders in remission, are mood\nstabilizers and antipsychotics effective and safe? Be involved in medicine choice in a supported\nremarks decision-making process. y the use of lithium should be considered as first-line y treatment with antipsychotic medicines/mood\nof treatment for bipolar disorder only ..."
}